28263460|t|Asunaprevir: An HCV Protease Inhibitor With Preferential Liver Distribution
28263460|a|Asunaprevir is an inhibitor of the hepatitis C virus (HCV) NS3/4A protease, demonstrating efficacy in clinical studies in patients infected with HCV genotype 1 or 4, with either peginterferon / ribavirin or combinations of direct-acting antivirals. Because of preferential distribution of asunaprevir to the liver via organic anion-transporting polypeptide (OATP)- mediated transport, asunaprevir demonstrates high apparent oral clearance and very low plasma concentrations. Asunaprevir plasma concentrations are markedly increased by single-dose rifampin (an OATP inhibitor) and in subjects with moderate to severe hepatic impairment. In addition, modestly higher plasma concentrations of asunaprevir have been noted in subjects infected with HCV relative to healthy subjects and in Asian subjects relative to whites. At the marketed dose, infrequent hepatic transaminase abnormalities were poorly predicted by plasma concentrations. For a compound with these characteristics, hepatic concentrations may have provided an improved understanding of the in vivo pharmacokinetic and pharmacodynamic data to support decision making during development.
28263460	0	11	Asunaprevir	T109,T121	C3491974
28263460	16	38	HCV Protease Inhibitor	T121	C4049839
28263460	57	62	Liver	T023	C0023884
28263460	63	75	Distribution	T039	C1378698
28263460	76	87	Asunaprevir	T109,T121	C3491974
28263460	94	150	inhibitor of the hepatitis C virus (HCV) NS3/4A protease	T121	C4049839
28263460	166	174	efficacy	T080	C1280519
28263460	178	194	clinical studies	T062	C0008972
28263460	198	206	patients	T101	C0030705
28263460	207	215	infected	T033	C0439663
28263460	221	235	HCV genotype 1	T005	C3532919
28263460	239	240	4	T005	C3532922
28263460	254	267	peginterferon	T116,T121,T129	C0982327
28263460	270	279	ribavirin	T114,T121	C0035525
28263460	283	295	combinations	T121	C0013162
28263460	299	323	direct-acting antivirals	T121	C3653501
28263460	336	361	preferential distribution	T039	C1378698
28263460	365	376	asunaprevir	T109,T121	C3491974
28263460	384	389	liver	T023	C0023884
28263460	394	432	organic anion-transporting polypeptide	T116,T123	C0949791
28263460	434	438	OATP	T116,T123	C0949791
28263460	441	459	mediated transport	T043	C0700215
28263460	461	472	asunaprevir	T109,T121	C3491974
28263460	500	504	oral	T030	C0226896
28263460	505	514	clearance	T080	C0449297
28263460	528	549	plasma concentrations	T081	C0683150
28263460	551	562	Asunaprevir	T109,T121	C3491974
28263460	563	584	plasma concentrations	T081	C0683150
28263460	598	607	increased	T081	C0205217
28263460	611	622	single-dose	T081	C0178602
28263460	623	631	rifampin	T109,T195	C0035608
28263460	636	640	OATP	T116,T123	C0949791
28263460	641	650	inhibitor	T080	C1999216
28263460	659	667	subjects	T098	C0080105
28263460	685	691	severe	T080	C0205082
28263460	692	710	hepatic impairment	T047	C0948807
28263460	741	762	plasma concentrations	T081	C0683150
28263460	766	777	asunaprevir	T109,T121	C3491974
28263460	797	805	subjects	T098	C0080105
28263460	806	814	infected	T033	C0439663
28263460	820	823	HCV	T005	C0220847
28263460	836	852	healthy subjects	T098	C1708335
28263460	860	865	Asian	T098	C0078988
28263460	866	874	subjects	T098	C0080105
28263460	887	893	whites	T098	C0080105
28263460	911	915	dose	T081	C0178602
28263460	917	927	infrequent	T079	C0521114
28263460	928	935	hepatic	T029	C0205054
28263460	936	948	transaminase	T116,T126	C0002594
28263460	949	962	abnormalities	T033	C0151625
28263460	988	1009	plasma concentrations	T081	C0683150
28263460	1017	1025	compound	T080	C0205198
28263460	1037	1052	characteristics	T080	C1521970
28263460	1054	1061	hepatic	T029	C0205054
28263460	1062	1076	concentrations	T081	C1446561
28263460	1128	1135	in vivo	T082	C1515655
28263460	1136	1151	pharmacokinetic	T062	C0201734
28263460	1156	1171	pharmacodynamic	T062	C1709518
28263460	1172	1176	data	T078	C1511726
28263460	1211	1222	development	T091	C0872152